Stock Market news at lse.co.uk - RSS News Feeds

Gw Pharmaceuticals Share News (GWP)



Share News for Gw Pharmaceuticals (GWP)


Share Price: 48.875Bid: 42.00Ask: 70.00Change: 0.00 (0.00%)No Movement on Gw Pharm.
Spread: 28.00Spread as %: 66.67%Open: 51.00High: 51.00Low: 48.00Yesterday’s Close: 48.875






BRIEF-GW Pharmaceuticals signs extension to Otsuka deal

LONDON, June 30 (Reuters) - GW Pharmaceuticals Plc: * Signed 3 year extension to global cannabinoid research collaboration with otsu
[30 Jun '10]

UPDATE 1-GW Pharma's cannabis drug to cost 11 pounds a day

By Ben Hirschler and Paul Sandle LONDON, June 21 (Reuters) - GW Pharmaceuticals Plc's cannabis-derived medicine Sativex will cost approxima
[21 Jun '10]

GW Pharma's cannabis drug to cost 11 pounds a day

LONDON, June 21 (Reuters) - GW Pharmaceuticals Plc's cannabis-derived medicine Sativex will cost approximately 11 pounds ($16.31) a day when use
[21 Jun '10]

Glance-PRESS DIGEST - British business - June 21

Monday June 21 2010 The Daily Telegraph LOCAL AUTHORITIY 'SICKIES' TWICE THOSE OF PRIVATE SECTOR Figures obtained from the govern
[21 Jun '10]

Glance-PRESS DIGEST - British business - June 19

Saturday June 19 2010 Daily Telegraph POISED TO DELIVER: OCADO SET FOR FLOTATION NEXT WEEK Online grocery delivery company Ocado
[19 Jun '10]

UPDATE 2-Britain approves GW Pharma's cannabis drug Sativex

By Ben Hirschler LONDON, June 18 (Reuters) - GW Pharmaceuticals Plc's cannabis-derived medicine Sativex has been approved in Britain for tr
[18 Jun '10]

UPDATE 1-Britain approves GW Pharma's cannabis drug Sativex

By Ben Hirschler LONDON, June 18 (Reuters) - GW Pharmaceuticals Plc's cannabis-derived medicine Sativex has been approved in Britain for tr
[18 Jun '10]

BRIEF-GW Pharma wins UK licence for cannabis drug Sativex

LONDON, June 18 (Reuters) - GW Pharmaceuticals: * UK regulator MHRA says GW Pharmaceuticals Plc wins UK licence for cannabis-derived drug s
[18 Jun '10]



Sign up for Live Prices





Datafeed and UK data supplied by NETbuilder and Interactive Data. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.